Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension

Author： Horn Evelyn M   Widlitz Allison C   Barst Robyn J  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.13, Iss.11, 2004-11, pp. : 1483-1492

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension

By O'Callaghan Dermot S   Savale Laurent   Yaïïci Azzedine   Natali Delphine   Jaïïs Xavier   Parent Florence   Montani David   Humbert Marc   Simonneau Géérald   Sitbon Olivier  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1585-1596

Informa Healthcare

Access to resources Recommend Favorite

Endothelin Receptor Antagonism: Role in the Treatment of Pulmonary Arterial Hypertension Related to Scleroderma

By Kabunga Peter   Coghlan Gerry  

Drugs, Vol. 68, Iss. 12, 2008-01 ,pp. : 1635-1645

Adis International

Access to resources Recommend Favorite

ZD1611, an Orally Active Endothelin-A Receptor Antagonist, Prevents Chronic Hypoxia-induced Pulmonary Hypertension in the Rat

By Bialecki R.A.   Fisher C.S.   Abbott B.M.   Barthlow H.G.   Caccese R.G.   Stow R.B.   Rumsey J.   Rumsey W.  

Pulmonary Pharmacology & Therapeutics, Vol. 12, Iss. 5, 1999-10 ,pp. : 303-312

Academic Press

Access to resources Recommend Favorite

Sitaxsentan STRIDEs ahead in pulmonary arterial hypertension

By  

Inpharma, Vol. 1, Iss. 1494, 2005-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Prolonged Anti-Hypertensive Effects of Oral Sitaxsentan, a Selective ETA Endothelin Receptor Antagonist, in Spontaneoulsy Hypertensive Hamsters

By Rubinstein Israel  

Cardiovascular Drugs and Therapy, Vol. 20, Iss. 5, 2006-10 ,pp. : 387-390

Springer Publishing Company

Access to resources Recommend Favorite